Defined Bacterial Consortia
Defined bacterial consortia as a differentiated modality to target gastrointestinal (GI) diseases (H2 relative to H1)
We are developing defined bacterial consortia as oral therapies to treat a wide range of debilitating diseases across multiple therapeutic areas, with an initial focus on gastrointestinal (GI) diseases in which gut dysbiosis — a disruption of the gut microbiota— is a known disease driver.
Gut Microbiota and its Role in Human Health (H3)
We are developing defined bacterial consortia as oral therapies to treat a wide range of debilitating diseases across multiple therapeutic areas, with an initial focus on gastrointestinal (GI) diseases in which gut dysbiosis — a disruption of the gut microbiota— is a known disease driver.
RESTORATiVE303 is a double-blind, placebo-controlled, Phase 3 study to evaluate the safety and efficacy of a 14-day course of VE303. The efficacy of VE303 will be assessed by comparing the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in study participants who receive VE303 and those who receive placebo.
A Live Biotherapeutic Product (LBP) is a biological product that: 1) contains live organisms, such as bacteria; 2) is applicable to the prevention, treatment, or cure of a disease or condition of human beings; and 3) is not a vaccine.
Cilinical Trials
Clinical Trial
We are currently conducting COLLECTiVE202, a randomized, double-blind, placebo-controlled, multinational Phase 2 study of VE202 in individuals with mild-to-moderate UC. The FDA has granted VE202 Fast Track designation for the treatment of adults with UC.
Manufacturing
Phasellus sagittis nunc eu tellus laoreet, et semper lectus scelerisque. In fringilla diam id purus facilisis ornare. In dapibus sapien aliquet elit sollicitudin tincidunt.
Intellectual Property
Phasellus sagittis nunc eu tellus laoreet, et semper lectus scelerisque. In fringilla diam id purus facilisis ornare. In dapibus sapien aliquet elit sollicitudin tincidunt.
Pipeline
Phasellus sagittis nunc eu tellus laoreet, et semper lectus scelerisque. In fringilla diam id purus facilisis ornare. In dapibus sapien aliquet elit sollicitudin tincidunt.
Pipeline
Phasellus sagittis nunc eu tellus laoreet, et semper lectus scelerisque. In fringilla diam id purus facilisis ornare. In dapibus sapien aliquet elit sollicitudin tincidunt.